Acino welcomes German court ruling on rivastigmine

Acino announces the achievement of another judicial success in the ongoing German intellectual property litigation proceedings regarding its generic rivastigmine patch.

Already in 2013, the district courts of Mannheim and Dusseldorf dismissed various originator complaints, taking the view that Acino’s product does not infringe any valid rivastigmine patent or utility model. In January 2015, in full accordance with the previous court decisions, the Munich Regional Court ruled in favor of Acino and its marketing partners. Although the decision is subject to appeal, this latest judicial judgment represents a key step forward and also significantly strengthens Acino’s position vis-à-vis its competitors.

Acino’s once-daily rivastigmine patch, the first generic alternative to the branded product, was first launched in 2013 in Germany and is currently marketed in key European countries including Italy, the Netherlands, Spain and the UK. Acino manufactures the rivastigmine patch at its state-of-the-art manufacturing facilities in Miesbach (Germany) and supplies its marketing partners with finished drug product for commercialization.